Gufic Biosciences (509079) Q1 25/26 earnings summary

Executive summary

• Indore facility reached 30% capacity utilization in FY 2026, driving revenue growth and operational scale-up, with global regulatory audits targeted for Q1 FY 2027.

• Achieved Q1 FY26 revenue of ₹226.96 crore, up 12% YoY, with EBITDA of ₹33.2 crore and margin of 14.6%.

• Strategic focus on expanding Critical Care, Ferticare, aesthetics (Stunnox), and international business, with new product launches and tech transfers underway.

• Expanded product pipeline and R&D advances in peptides, dual chamber syringes, and immuno-oncology (Selvax) pipeline.

• Board approved unaudited financial results for Q1 FY26 and re-appointed cost and statutory auditors.

Financial highlights

• Q1 FY26 revenue was ₹226.96 crore, up from ₹205 crore in Q4 FY25 and ₹202.8 crore YoY, mainly due to Indore facility ramp-up.

• EBITDA rose to ₹33.2 crore (14.6% margin), up from ₹27 crore sequentially, but down from 18.2% YoY.

• PAT for Q1 FY26 at ₹12.1 crore, down from ₹20.9 crore YoY; PAT margin at 5.3% vs 10.3% YoY.

• Export revenue accounted for 20% of total, with ₹53 crore in Q1.

• Standalone and consolidated net profit for Q1 FY26 were ₹1,207.33 lakhs and ₹1,307.04 lakhs, respectively.

Outlook and guidance

• Indore expected to reach breakeven EBITDA in FY26 and become a margin accretive asset from FY27.

• Capacity utilization at Indore projected to reach 30% by year-end, with further scale-up planned.

• Exports from Indore to begin post-EU approval, targeted by Q1 FY27; additional export markets in Southeast Asia and Africa to open in next 6-12 months.

• Focus on expanding regulated market presence, scaling CMO, and commercializing pipeline products.

• Board re-appointed cost and statutory auditors, indicating continuity in financial oversight.